Research

Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: A double blind, placebo, controlled randomized clinical trial 

This randomized, double-blind, placebo-controlled clinical study from 2015 showed that MS patients receiving 500 mg/day of CoQ10 for 12 weeks presented with a significant decrease of inflammatory cytokine. CoQ10 also alleviates markers of CNS inflammation.  

References:

Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B, Jazayeri S, Gohari MR, Aryaeian N. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015 May;18(4):169-76. doi: 10.1179/1476830513Y.0000000106. Epub 2014 Jan 10. PMID: 24621064. 

Ingredient in this research

Let’s keep in touch

Don’t worry we only send updates monthly on offers, product changes, and new opportunities for you.

Due to increased order volumes, some orders may experience shipping delays. Thank you for your patience and understanding.
×
Why Choose to Subscribe and Save?
  • Automatically re-order your favorite products on your schedule.
  • Easily change the products or shipping date for your upcoming Scheduled Orders.
  • If you decide a subscription is not for you, it can be cancelled after 2 renewals.